ALKEM:NSE:NSE-Alkem Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 6194.15

Change

+34.85 (+0.57)%

Market Cap

USD 740.60B

Volume

0.33M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also provides vitamins, minerals, and nutrients, as well as mouth wash, shampoos, pregnancy detection kits, and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India. Address: Alkem House, Mumbai, India, 400013

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

-0.80 (-0.04%)

USD 4,554.89B
DIVISLAB:NSE Divi's Laboratories Limited

-4.75 (-0.09%)

USD 1,441.57B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+81.40 (+2.40%)

USD 1,154.88B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-102.40 (-1.52%)

USD 1,121.95B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

-11.70 (-1.09%)

USD 1,071.49B
MANKIND:NSE Mankind Pharma Ltd

+73.85 (+2.91%)

USD 1,033.59B
LUPIN:NSE Lupin Limited

+14.65 (+0.67%)

USD 998.11B
AUROPHARMA:NSE Aurobindo Pharma Limited

+7.45 (+0.51%)

USD 851.48B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

+18.35 (+1.12%)

USD 473.60B
AJANTPHARM:NSE Ajanta Pharma Limited

-26.20 (-0.78%)

USD 418.19B

ETFs Containing ALKEM:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.98% 42% F 53% F
Dividend Return 0.78% 70% C- 61% D-
Total Return 21.76% 43% F 53% F
Trailing 12 Months  
Capital Gain 75.85% 72% C 77% C+
Dividend Return 1.14% 71% C- 67% D+
Total Return 76.98% 71% C- 77% C+
Trailing 5 Years  
Capital Gain 219.46% 41% F 48% F
Dividend Return 7.32% 70% C- 48% F
Total Return 226.78% 43% F 48% F
Average Annual (5 Year Horizon)  
Capital Gain 22.30% N/A N/A 32% F
Dividend Return 23.28% N/A N/A 33% F
Total Return 0.98% N/A N/A 63% D
Risk Return Profile  
Volatility (Standard Deviation) 24.25% N/A N/A 84% B
Risk Adjusted Return 96.03% N/A N/A 80% B-
Market Capitalization 740.60B 90% A- 93% A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.